Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Outlook

Thelansis's "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Inflammatory Demyelinating Polyneuropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Overview

Chronic Inflammatory Demyelinating Polyneuropathy is an immune-mediated peripheral neuropathy driven by T-cell and autoantibody-mediated myelin destruction, causing progressive or relapsing proximal and distal limb weakness with sensory impairment. Patients present with symmetric weakness, areflexia, gait instability, and sensory disturbance evolving over months. Diagnosis combines nerve conduction studies showing demyelination, CSF cytoalbuminous dissociation, and nerve biopsy when indicated; disability scales reflect severity. Corticosteroids, intravenous immunoglobulin, and plasma exchange are established first-line treatments; subcutaneous immunoglobulin offers convenient maintenance. Subcutaneous efgartigimod is an approved FcRn-targeted option reducing pathogenic IgG and relapse risk. Regular neurological assessments guide therapy escalation. Early treatment and multidisciplinary rehabilitation support sustained remission.

Key Highlights

• In France, the prevalent CIDP population is projected to increase from approximately 3,808 in 2025 to 3,992 by 2035.
• CIDP is a rare autoimmune neurological disorder characterized by progressive weakness and sensory dysfunction.
• Early diagnosis and treatment remain critical to preventing irreversible nerve damage and disability.
• Immunoglobulin therapy continues to represent the cornerstone of disease management.
• Emerging targeted immunotherapies are expanding treatment options for refractory disease.

Market Overview

• The Italy CIDP market is projected to grow from approximately $145 MN to $375 MN by 2035.
• Market growth is supported by:
• Increasing utilization of IVIG, SCIG, and targeted immunotherapies
• Improved diagnosis and long-term disease management
• Market value growth is driven by chronic treatment requirements and increasing adoption of advanced therapies.
• Future growth will depend on novel immune-modulating therapies and improved long-term disease control strategies.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Takeda
• Kine Sciences Co., Ltd.
• Immunovant Sciences GmbH
• Argenx
• Grifols Therapeutics LLC
• Nuvig Therapeutics, Inc.
• Sanofi
• Kite, A Gilead Company
• Janssen Research & Development, LLC
• Kedrion S.p.A.